NR4A1 and breast carcinoma: As VDR, RXR and PPARγ can be quantified in cancer tissue easily, they - given them being present in BRCA1 mutated breast cancer cases at all - may evolve as novel alternative biomarkers, especially for hormone receptor negative or even triple negative breast cancer patients.